GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
pure daytrade on a penny stock.OOOpha be careful here down quite a bit,> Now $1.53
Why the hell would it be down 9% in the pre that's prob a fake print-
$1.53-0.10(-6.13%)8:00 AM 11/25/22
NASDAQ |$USD |Pre-Market:$1.39-0.14(-9.15%)3:38 AM
1 year down 97%3% more and it disappears!
long gone.
GBA HOLIDAY SIX PACK
MAKE THIS YOUR CHRISTMAS 6 PACK-----
HOLD THRU X-MAS!!
(w/entry price)
A)PRVB Provention Bio, Inc.
$7.95
B)EE Excelerate Energy, Inc.
$27.50
C)WBA Walgreens Boots Alliance, Inc.
$40.60
D)CAE CAE Inc.
$21.43
E)Man U.
$17.50
F)MRTX
$88.00
MAKE THIS YOUR CHRISTMAS 6 PACK-----
HOLD THRU X-MAS!!
(w/entry price)
A)PRVB Provention Bio, Inc.
$7.95
B)EE Excelerate Energy, Inc.
$27.50
C)WBA Walgreens Boots Alliance, Inc.
$40.60
D)CAE CAE Inc.
$21.43
E)Man U.
$17.50
F)MRTX
$88.00
Last edited:
Pinduoduo is the China stock everyone wants today!
PDD
The savant got in early at $66
You were either sleeping or listening to the radio.
Van can we hold MANU through X-Mas?
I'd like to keep the portfolio static. But this investment is 100% based around the buyout
possibilities... Could swing back if Apple says they are no longer interested. What do you think?
I'd like to keep the portfolio static. But this investment is 100% based around the buyout
possibilities... Could swing back if Apple says they are no longer interested. What do you think?
If it goes up much from here, it'll be because the short interest is climbing daily.
I don't think Apple's Board would approve this, if it was in fact true.
They'd be better off buying Formula-E and flipping it to Disney.
I called it out at $15. I didn't buy any though.
If I were you, I'd take some off the table unless you feel confident there will in fact be a short squeeze.
That said, the figure I used as to what someone would be willing to pay for the franchise was from 2020. Hell that # might be 30% higher, which would value the shares around $30
Stoney!!!!
Wake up.
Gummy penny stock of the day.
NRBO---> $1.74
>They have $7.15 cash/share.
>$180/share two years ago.
>Goldman just bought a million shares.
>Oral Covid treatment in Phase ii clinicals.
>Plus a couple other drugs for neurodegenerative (things).
>5 employees. (keeps the overhead down)
Sorry I didn't read Gummy what day was this anyway? Fri after thanks?
Could GS be angling to swallow up the company? Why would they buy one mil shares?
VC fund?
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022:
34th Annual Piper Sandler Healthcare Conference
5th Annual Evercore ISI HealthCONx Conference
Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in moderated discussions at the Piper Sandler conference on Tuesday, November 29th, at 11:00 am ET and at the Evercore ISI conference on Thursday, December 1st at 8:00 am ET.
A simultaneous webcast of both discussions will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcast will be available for two weeks following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
34th Annual Piper Sandler Healthcare Conference
5th Annual Evercore ISI HealthCONx Conference
Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in moderated discussions at the Piper Sandler conference on Tuesday, November 29th, at 11:00 am ET and at the Evercore ISI conference on Thursday, December 1st at 8:00 am ET.
A simultaneous webcast of both discussions will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcast will be available for two weeks following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
I believe no, similar name Bio maybe,,,,
I do know the co. They have a MAY 2023 date with the FDA. on a heart med.
sotagliflozin treatment,-? It sounded good.
This is the play here.... you have me interested. //
One reason a competitor Asta Zenica had an inferior result in the same area)))))
AstraZeneca hazard ratio notably weaker than Lexicon, says Citi 08/29/22 LXRX, AZN Citi analyst Yigal Nochomovitz says that over the weekend, AstraZeneca (AZN) disclosed a hazard ratio for cardiovascular death, hospitalization for heart failure or urgent heat failure of 0.82 in the Phase 3 DELIVER trial testing dapagliflozin in dapagliflozin in heart failure and preserved ejection fraction. This is notably a weaker relative-risk reduction than the 0.63 hazard ratio Lexicon Pharmaceuticals has demonstrated for sotagliflozin in HFpEF patients in the pooled analysis of SOLOIST and SCORED, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on Lexicon with a $16 price target.
Very old comment obviously but hey that PT--> $16????? ~si